Skip to main content

Table 3 Baseline clinical and biological characteristics of coagulopathic patients in the placebo and rFVIIa groups

From: Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials

 

Placebo group (n = 76)

rFVIIa group (n = 60)

Age (years)

34 ± 12

31 ± 11

Gender

  

   Men

63 (83%)

51 (85%)

   Women

13 (17%)

9 (15%)

Type of trauma

  

   Penetrating

38 (50%)

35 (58%)

   Blunt

38 (50%)

25 (42%)

Injury severity score

30 ± 13

30 ± 13

Number of body regions injured

  

   1

16 (21%)

13 (22%)

   2–3

40 (53%)

29 (48%)

   >3

18 (24%)

17 (28%)

   Unknown

2 (3%)

1 (2%)

Systolic blood pressure (mm Hg)

103 ± 26

109 ± 31

Mean arterial pressure (mm Hg)

74 ± 22

78 ± 23

Body temperature (°C)

35.2 ± 1.6

35.6 ± 1.1

pH

7.27 ± 0.11

7.29 ± 0.10

Hematocrit (percentage)

23 ± 8

26 ± 7

aPTT (seconds)

54 ± 24

46 ± 26

PT (seconds)

20 ± 5

17 ± 7

Fibrinogen (g/l)

1.3 ± 0.8

1.4 ± 0.6

Platelets (× 109)

70 ± 42

87 ± 47

  1. Data are mean ± standard deviation or number (percentage). No significant statistical differences between groups were observed. aPTT, activated partial thromboplastin time; PT, prothrombin time; rFVIIa, recombinant activated factor VII.